The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Sidapvia (dapagliflozin+sitagliptin)
Australian Public Assessment Report
Device/Product Name
Sidapvia
Active ingredients
Dapagliflozin 10 mg and sitagliptin 100 mg
AusPAR Date
Published
Sponsor
Submission Number
PM-2023-00672-1-5
Submission Type
New fixed dose combination
Decision
Approved